ArticleWorld journal of surgical oncology2025
Predictive value of 18F-FDG-PET/CT for pathologic complete response (pCR) of lesions after neoadjuvant chemotherapy in advanced ovarian cancer.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study aimed to evaluate the ability of 18F-FDG-PET/CT to predict pathological complete response (pCR) in lesions of patients with advanced epithelial ovarian cancer (EOC) following neoadjuvant chemotherapy (NACT). We assessed whether 18F-FDG-PET/CT could predict lesion-specific pCR prior to interval debulking surgery (IDS), thus guiding precise lesion resection.
methodsTwenty-four patients with advanced EOC underwent IDS after NACT. 18F-FDG-PET/CT imaging was performed before and after NACT, with the maximum standardized uptake value (SUVmax) recorded for each metabolically active site. The relationship between the relative change in SUVmax (ΔSUVmax) of grossly visible or suspicious lesions resected during IDS and their pCR status was analyzed. Additionally, the association between omental ΔSUVmax and the chemotherapy response score (CRS) and CA125 elimination rate constant K (KELIM) score was examined.
resultsTumor lesion ΔSUVmax Post-NACT was significantly associated with pCR (P < 0.001, odds ratio [OR] 0.001, 95% confidence interval [CI]: 0.000-0.012). A reduction in SUVmax > 60.2% predicted pCR in lesions (sensitivity 75.6%, specificity 79.2%), with an area under the curve (AUC) of 0.817 (95% CI: 0.756-0.877, P < 0.05). Site-Stratified analysis showed that reductions > 59.6% in peritoneal implants (sensitivity 71.4%, specificity 95.7%, AUC 0.905, 95% CI: 0.821-0.989, P < 0.05), > 63.95% in metastatic lymph nodes (sensitivity 72.7%, specificity 94.4%, AUC 0.904, 95% CI: 0.815-0.994, P < 0.05) predicted pCR at respective sites, and reductions > 73.9% in primary lesions (sensitivity 100%, specificity 78.9%, AUC 0.816, 95% CI: 0.642-0.990, P = 0.151) predicted a trend toward significance in pCR results. Omental ΔSUVmax differed significantly between CRS1/2 and CRS3 groups (t = 3.404,P = 0.003); a reduction > 49.95% predicted CRS3 (sensitivity 83.3%, specificity 78.6%, AUC 0.893, 95% CI: 0.736-1.000, P < 0.05). Omental ΔSUVmax was positively correlated with the KELIM score (r = 0.712, P < 0.001), and primary lesion ΔSUVmax was also significant associated with KELIM score (r = 0.547, P = 0.015).
conclusion18F-FDG-PET/CT can predict lesion-specific pCR after NACT in advanced EOC, providing guidance for the extent of IDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.